Last reviewed · How we verify
albendazole and praziquantel
Albendazole and praziquantel are anthelmintic agents that disrupt microtubule formation and calcium homeostasis in parasitic worms, leading to their paralysis and death.
Albendazole and praziquantel are anthelmintic agents that disrupt microtubule formation and calcium homeostasis in parasitic worms, leading to their paralysis and death. Used for Helminthic infections (roundworms, tapeworms, flukes), Polyparasitic infections.
At a glance
| Generic name | albendazole and praziquantel |
|---|---|
| Also known as | Albendazole, Praziquantel, ABZ+PZQ, ABZ+PZQ PCB |
| Sponsor | R-Evolution Worldwide S.r.l. Impresa Sociale |
| Drug class | Anthelmintic combination |
| Target | β-tubulin (albendazole); calcium channels (praziquantel) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | FDA-approved |
Mechanism of action
Albendazole inhibits β-tubulin polymerization in helminth microtubules, preventing glucose uptake and energy production. Praziquantel increases cell membrane permeability to calcium in trematodes and cestodes, causing muscle contraction and paralysis. Together, they provide broad-spectrum activity against multiple parasitic worm species.
Approved indications
- Helminthic infections (roundworms, tapeworms, flukes)
- Polyparasitic infections
Common side effects
- Abdominal pain
- Nausea
- Diarrhea
- Headache
- Dizziness
Key clinical trials
- Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel (PHASE4)
- HIV And Parasitic Infection (HAPI) Study (NA)
- Oxfendazole in Mild Parenchymal Brain Cysticercosis (PHASE2, PHASE3)
- Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis (PHASE4)
- Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control (NA)
- Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO) (PHASE3)
- Feasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children (NA)
- Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: